TrialThe Lancet. Oncology2018

Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.

Giles W Robinson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.